Industry News
FDA approves first Factor X concentrate to treat patients with rare hereditary bleeding disorder
10/21/2015
The U.S. Food and Drug Administration has approved Coagadex, Coagulation Factor X (Human), for hereditary Factor X (10) deficiency.
Patients with an early-stage, indolent form of lymphoma are increasingly being given no treatment, chemotherapy or targeted drug therapies despite strong clinical evidence that shows radiation...
FDA approves first Factor X concentrate to treat patients with rare hereditary bleeding disorder
10/21/2015
The U.S. Food and Drug Administration has approved Coagadex, Coagulation Factor X (Human), for hereditary Factor X (10) deficiency.
Scientists crunch 'big data' to produce new catalog of cancer driver genes
10/21/2015
An analysis of two huge cancer databases identifies over 100 new cancer driver genes and helps explain how tumors driven by the same gene may lead to different patient outcomes.
Botox prevents heart problems following bypass surgery
10/21/2015
Botox appears to prevent heart rhythm problems in patients following bypass surgery, according to an article published by the AHA.
Botox prevents heart problems following bypass surgery
10/21/2015
Botox appears to prevent heart rhythm problems in patients following bypass surgery, according to an article published by the AHA.
Histone deacetylase 6 inhibition enhances oncolytic viral therapy
10/21/2015
Gliomas are extremely aggressive brain tumors that are resistant to standard cancer therapeutics.
Results strengthen the foundation for current radiation protection standardsMore precise estimates of cancer risks associated with prolonged, low level exposure to ionising radiation among...
A new way to starve lung cancer?
10/20/2015
Metabolic alterations in lung cancer may open new avenues for treating the diseaseScientists have identified a new way to stop the growth of lung cancer cells, by blocking their ability to use...
UGR scientists patent an effective drug for treating breast, colon, and skin cancers
10/20/2015
Reduced the tumor activity by 50 percent following 41 days of treatmentScientists from the University of Granada (UGR) have patented an effective drug for treating cancer stem cells (CSCs) in...